TG

Tenac.Io Gmbh

www.tenac.io link_icon

Company Research Report: Tenacio



Company Overview



  • Name: Tenacio

  • Mission: Tenacio is committed to improving outcomes for patients with cardiovascular diseases by providing comprehensive risk assessments and treatment recommendations to optimize cardiovascular (CV) care.

  • Year Founded and Founders: No information is available.

  • Key People: The founders and team are dedicated to improving the lives of patients with cardiovascular disease through state-of-the-art knowledge, big data analysis, and artificial intelligence.

  • Headquarters:

  • Tenac.io GmbH, Am Hamburger Bahnhof 2A, 10557 Berlin, Germany

  • Tenac.io Inc., 447 Broadway, 2nd Floor, New York, NY 10013, USA

  • Number of Employees: No information is available.

  • Revenue: No information is available.

  • What is the Company Known For: Tenacio is known for its digital health solutions focusing on cardiovascular disease prevention and treatment optimization through advanced data analytics and personalized treatment plans.


Products



OptiCor



  • Description: OptiCor is designed to provide individual risk-based treatment recommendations for patients with cardiovascular diseases.

  • Key Features:

  • Algorithm: Utilizes a validated algorithm to predict the risk of mortality, stroke, and bleeding based on individual clinical data.

  • Individual Risk Visualization: Offers a visual representation of the patient’s risk and the potential impact of optimized treatment, accessible to both physicians and patients.

  • Optimized Treatment Plan: Provides a guideline-based, individual, and practical treatment optimization plan.

  • EHR Integration: Compatible with existing clinical practice workflows and electronic health records (EHR).


OriCor



  • Description: OriCor is aimed at increasing the probability of success for biopharmaceutical and medical device manufacturers by optimizing trial recruitment through targeted patient identification.

  • Key Features:

  • Patient Screening for Trial Recruitment: Identification of patients using a validated algorithm to meet defined criteria for clinical trials.

  • Individual CV Risk Identification: Enhances trial recruitment by screening patients based on their cardiovascular risk profiles.


Recent Developments



  • Recent Awards:

  • Won the 2024 Digital Health Pitch Competition Award at the Digital Therapeutics Alliance Summit.


  • New Partnerships:

  • Joined the Innovators' Network at the American Heart Association Center for Health Technology in May 2024.


  • Product Updates:

  • January 2024: Unveiled an enhanced version of OptiCor, empowering clinicians to implement the ACC/AHA 2023 Atrial Fibrillation (AF) guidelines.


  • Product Launches:

  • January 2023: Launched the OptiCor patient management platform in the US.


Memberships & Recognitions



  • Recognized as one of the “Most Innovative AI-Based Digital Health Start-Ups” in 2021.

  • Established an International Scientific Advisory Board in January 2022.

  • Published a benefit analysis in the European Heart Journal Digital Health in April 2022.


Contact Information



  • Germany: Tenac.io GmbH, Am Hamburger Bahnhof 2A, 10557 Berlin, Germany

  • USA: Tenac.io Inc., 447 Broadway, 2nd Floor, New York, NY 10013, USA

  • Contact Email: info@tenac.io

  • Phone: +1 (212) 252-2168


For continued updates and resources, individuals are encouraged to subscribe to Tenacio's mailing list for the latest articles and news in digital cardiovascular care.